MEVALOTIN

Mevalotin Adverse Events Reported to the FDA Over Time

How are Mevalotin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Mevalotin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Mevalotin is flagged as the suspect drug causing the adverse event.

Most Common Mevalotin Adverse Events Reported to the FDA

What are the most common Mevalotin adverse events reported to the FDA?

Rhabdomyolysis	57 (7.29%)
Hepatic Function Abnormal	28 (3.58%)
Blood Creatine Phosphokinase Increa...	27 (3.45%)
Aspartate Aminotransferase Increase...	21 (2.69%)
Alanine Aminotransferase Increased	17 (2.17%)
Liver Disorder	17 (2.17%)
Renal Failure Acute	14 (1.79%)
Blood Lactate Dehydrogenase Increas...	13 (1.66%)
Dehydration	12 (1.53%)
Platelet Count Decreased	12 (1.53%)
Renal Impairment	11 (1.41%)
	Show More
Chest Pain	9 (1.15%)
Eosinophil Count Increased	9 (1.15%)
Loss Of Consciousness	9 (1.15%)
Malaise	8 (1.02%)
Monoplegia	8 (1.02%)
Pyrexia	8 (1.02%)
Blood Alkaline Phosphatase Increase...	7 (.9%)
Cardiac Failure	7 (.9%)
Chest Discomfort	7 (.9%)
Jaundice	7 (.9%)
Pneumonia	7 (.9%)
Prostate Cancer	7 (.9%)
Acute Generalised Exanthematous Pus...	6 (.77%)
Acute Respiratory Distress Syndrome	6 (.77%)
Aortic Dissection	6 (.77%)
Blood Creatinine Increased	6 (.77%)
C-reactive Protein Increased	6 (.77%)
Dyspnoea	6 (.77%)
Gamma-glutamyltransferase Increased	6 (.77%)
Anaphylactic Shock	5 (.64%)
Chromaturia	5 (.64%)
Condition Aggravated	5 (.64%)
Delirium	5 (.64%)
Depressed Level Of Consciousness	5 (.64%)
Disseminated Intravascular Coagulat...	5 (.64%)
Dizziness	5 (.64%)
Interstitial Lung Disease	5 (.64%)
Musculoskeletal Pain	5 (.64%)
Myocardial Infarction	5 (.64%)
Oedema Peripheral	5 (.64%)
Pneumonitis	5 (.64%)
Renal Failure	5 (.64%)
Respiratory Failure	5 (.64%)
Acute Myocardial Infarction	4 (.51%)
Agranulocytosis	4 (.51%)
Anaemia	4 (.51%)
Bile Duct Stone	4 (.51%)
Cardio-respiratory Arrest	4 (.51%)
Cardiogenic Shock	4 (.51%)
Cerebral Haemorrhage	4 (.51%)
Cerebral Infarction	4 (.51%)
Contusion	4 (.51%)
Cyanosis	4 (.51%)
Drug Eruption	4 (.51%)
Electrocardiogram Abnormal	4 (.51%)
Electrocardiogram St Segment Depres...	4 (.51%)
Erythema Multiforme	4 (.51%)
Haemorrhage Subcutaneous	4 (.51%)
Idiopathic Thrombocytopenic Purpura	4 (.51%)
Muscular Weakness	4 (.51%)
Palpitations	4 (.51%)
Pneumonia Aspiration	4 (.51%)
Vascular Resistance Systemic Decrea...	4 (.51%)
Angina Unstable	3 (.38%)
Aortic Surgery	3 (.38%)
Asthenia	3 (.38%)
Blood Pressure Increased	3 (.38%)
Blood Urea Increased	3 (.38%)
Decreased Appetite	3 (.38%)
Drug Rash With Eosinophilia And Sys...	3 (.38%)
Erythema	3 (.38%)
Fall	3 (.38%)
Headache	3 (.38%)
Hepatitis	3 (.38%)
Infection	3 (.38%)
Liver Function Test Abnormal	3 (.38%)
Movement Disorder	3 (.38%)
Myositis	3 (.38%)
Peripheral Coldness	3 (.38%)
Reflux Oesophagitis	3 (.38%)
Sense Of Oppression	3 (.38%)
Urine Output Decreased	3 (.38%)
Weight Increased	3 (.38%)
White Blood Cell Count Decreased	3 (.38%)
Angina Pectoris	2 (.26%)
Arrhythmia	2 (.26%)
Arthralgia	2 (.26%)
Asthma	2 (.26%)
Blood Amylase Increased	2 (.26%)
Blood Glucose Increased	2 (.26%)
Blood Immunoglobulin E Increased	2 (.26%)
Capillary Disorder	2 (.26%)
Cardiac Pacemaker Insertion	2 (.26%)
Cellulitis	2 (.26%)
Cholestasis	2 (.26%)
Circulatory Collapse	2 (.26%)
Constipation	2 (.26%)
Coronary Angioplasty	2 (.26%)
Coronary Artery Occlusion	2 (.26%)
Cytolytic Hepatitis	2 (.26%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Mevalotin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mevalotin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Mevalotin

What are the most common Mevalotin adverse events reported to the FDA?

Muscle	66 (8.44%)
Hepatic And Hepatobiliary	64 (8.18%)
Hepatobiliary	49 (6.27%)
Enzyme	48 (6.14%)
Renal Disorders	35 (4.48%)
Epidermal And Dermal Conditions	32 (4.09%)
Hematology Investigations	29 (3.71%)
Neurological	23 (2.94%)
Lower Respiratory Tract Disorders	22 (2.81%)
Cardiac And Vascular Investigations	17 (2.17%)
Coronary Artery	17 (2.17%)
	Show More
Respiratory	17 (2.17%)
Renal And Urinary Tract Investigati...	16 (2.05%)
Infections - Pathogen Unspecified	15 (1.92%)
Electrolyte And Fluid Balance Condi...	14 (1.79%)
Heart Failures	12 (1.53%)
Movement Disorders	11 (1.41%)
Central Nervous System Vascular	10 (1.28%)
Cardiac Arrhythmias	9 (1.15%)
Injuries	9 (1.15%)
Body Temperature Conditions	8 (1.02%)
Cardiac Disorder Signs	8 (1.02%)
Reproductive Neoplasms Male Maligna...	8 (1.02%)
Allergic Conditions	7 (.9%)
Decreased And Nonspecific Blood Pre...	7 (.9%)
Urinary Tract Signs	7 (.9%)
Anemias Nonhemolytic And Marrow Dep...	6 (.77%)
Aneurysms And Artery Dissections	6 (.77%)
Gastrointestinal Signs	6 (.77%)
Musculoskeletal And Connective Tiss...	6 (.77%)
Platelet	6 (.77%)
Protein And Chemistry Analyses	6 (.77%)
White Blood Cell	6 (.77%)
Appetite And General Nutritional	5 (.64%)
Bacterial Infectious	5 (.64%)
Coagulopathies And Bleeding Diathes...	5 (.64%)
Deliria	5 (.64%)
Vascular Therapeutic Procedures	5 (.64%)
Bile Duct	4 (.51%)
Immunology And Allergy	4 (.51%)
Physical Examination Topics	4 (.51%)
Skin Vascular Abnormalities	4 (.51%)
Arteriosclerosis, Stenosis, Vascula...	3 (.38%)
Bronchial Disorders	3 (.38%)
Gastrointestinal Inflammatory Condi...	3 (.38%)
Gastrointestinal Motility And Defec...	3 (.38%)
Headaches	3 (.38%)
Vascular Hypertensive	3 (.38%)
Angiedema And Urticaria	2 (.26%)
Cardiac Therapeutic Procedures	2 (.26%)
Fatal Outcomes	2 (.26%)
Gastrointestinal	2 (.26%)
Hematological And Lymphoid Tissue T...	2 (.26%)
Hepatic And Biliary Neoplasms Benig...	2 (.26%)
Inner Ear And Viiith Cranial Nerve	2 (.26%)
Joint	2 (.26%)
Lipid Analyses	2 (.26%)
Metabolic, Nutritional And Blood Ga...	2 (.26%)
Metabolism	2 (.26%)
Musculoskeletal And Connective Tiss...	2 (.26%)
Musculoskeletal And Soft Tissue Inv...	2 (.26%)
Nephropathies	2 (.26%)
Neuromuscular	2 (.26%)
Ocular Infections, Irritations And ...	2 (.26%)
Oral Soft Tissue Conditions	2 (.26%)
Procedural And Device Related Injur...	2 (.26%)
Salivary Gland Conditions	2 (.26%)
Skin Appendage Conditions	2 (.26%)
Tongue Conditions	2 (.26%)
Upper Respiratory Tract Disorders	2 (.26%)
Vascular	2 (.26%)
Ancillary Infectious Topics	1 (.13%)
Anterior Eye Structural Change, Dep...	1 (.13%)
Benign Neoplasms Gastrointestinal	1 (.13%)
Connective Tissue Disorders	1 (.13%)
Dental And Gingival Conditions	1 (.13%)
Eating Disorders	1 (.13%)
Exocrine Pancreas Conditions	1 (.13%)
Gastrointestinal Ulceration And Per...	1 (.13%)
Glucose Metabolism Disorders	1 (.13%)
Hematopoietic Neoplasms	1 (.13%)
Hemolyses And Related Conditions	1 (.13%)
Injuries By Physical Agents	1 (.13%)
Lipid Metabolism	1 (.13%)
Mental Impairment	1 (.13%)
Metastases	1 (.13%)
Myocardial	1 (.13%)
Pigmentation	1 (.13%)
Psychiatric Therapeutic Procedures	1 (.13%)
Seizures	1 (.13%)
Skin And Subcutaneous Tissue Therap...	1 (.13%)
Therapeutic And Nontherapeutic Effe...	1 (.13%)
Vascular Inflammations	1 (.13%)
Viral Infectious	1 (.13%)
Vision	1 (.13%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Mevalotin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Mevalotin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.